头孢洛林在社区获得性细菌性肺炎治疗中的临床评价。
Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia.
机构信息
University of Texas Health Science Center, San Antonio, Texas.
出版信息
Infect Drug Resist. 2012;5:43-51. doi: 10.2147/IDR.S17433. Epub 2012 Feb 1.
Abstract
Ceftaroline fosamil (ceftaroline) was recently approved for the treatment of community- acquired pneumonia (CAP) and complicated skin infections. This newly developed cephalosporin possesses a broad spectrum of activity against gram-positive and gram-negative bacteria. Most importantly, ceftaroline demonstrates potent in vitro antimicrobial activity against multi-drug resistant Streptococcus pneumoniae and methicillin-resistant strains of Staphylococcus aureus. In two Phase III, double-blinded, randomized, prospective trials (FOCUS 1 and FOCUS 2), ceftaroline was shown to be non-inferior to ceftriaxone for the treatment of CAP in hospitalized patients. Ceftaroline exhibits low resistance rates and a safety profile similar to that of other cephalosporins. In this review, we will evaluate the pharmacological characteristics, safety, antimicrobial properties, and efficacy of ceftaroline and its applications in the treatment of CAP.
摘要
头孢洛林酯（头孢洛林）最近被批准用于治疗社区获得性肺炎（CAP）和复杂性皮肤感染。这种新开发的头孢菌素对革兰氏阳性菌和革兰氏阴性菌具有广泛的活性。最重要的是，头孢洛林对多药耐药肺炎链球菌和耐甲氧西林金黄色葡萄球菌具有强大的体外抗菌活性。在两项 III 期、双盲、随机、前瞻性试验（FOCUS1 和 FOCUS2）中，头孢洛林在治疗住院患者的 CAP 方面被证明不劣于头孢曲松。头孢洛林具有较低的耐药率和与其他头孢菌素相似的安全性。在这篇综述中，我们将评估头孢洛林的药理学特性、安全性、抗菌特性和疗效及其在 CAP 治疗中的应用。
相似文献
1
Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia.头孢洛林在社区获得性细菌性肺炎治疗中的临床评价。
Infect Drug Resist. 2012;5:43-51. doi: 10.2147/IDR.S17433. Epub 2012 Feb 1.
2
Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.头孢洛林酯治疗社区获得性细菌性肺炎和急性细菌性皮肤和皮肤结构感染。
Drugs. 2012 Jul 30;72(11):1473-93. doi: 10.2165/11635660-000000000-00000.
3
Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults.头孢洛林酯氨丁三醇作为一种潜在的治疗成人社区获得性肺炎金黄色葡萄球菌的治疗选择。
Int J Antimicrob Agents. 2019 Oct;54(4):410-422. doi: 10.1016/j.ijantimicag.2019.08.012. Epub 2019 Aug 9.
4
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.重点 1：头孢洛林酯氨噻肟与头孢曲松治疗社区获得性肺炎的疗效和安全性的随机、双盲、多中心、III 期临床试验。
J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii19-32. doi: 10.1093/jac/dkr096.
5
Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.头孢洛林酯：在治疗复杂性皮肤和软组织感染及社区获得性肺炎中的应用评价。
Drugs. 2013 Jul;73(10):1067-94. doi: 10.1007/s40265-013-0075-6.
6
FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.重点 2：头孢洛林酯氨噻肟与头孢曲松治疗社区获得性肺炎的疗效和安全性的随机、双盲、多中心 III 期临床试验。
J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii33-44. doi: 10.1093/jac/dkr097.
7
[Ceftaroline fosamil in community-acquired and nosocomial pneumonia].[头孢洛林酯用于社区获得性和医院获得性肺炎]
Enferm Infecc Microbiol Clin. 2014 Mar;32 Suppl 2:38-43. doi: 10.1016/S0213-005X(14)70157-0.
8
Review of ceftaroline fosamil microbiology: integrated FOCUS studies.头孢洛林酯磷酸钠微生物学评价：整合 FOCUS 研究。
J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii45-51. doi: 10.1093/jac/dkr098.
9
A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone.头孢洛林与头孢曲松治疗儿童社区获得性肺炎的随机前瞻性研究
Pediatr Infect Dis J. 2016 Jul;35(7):752-9. doi: 10.1097/INF.0000000000001159.
10
Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens.头孢卡品酯：一种对耐药革兰阳性病原体具有活性的新型头孢菌素。
Pharmacotherapy. 2010 Apr;30(4):375-89. doi: 10.1592/phco.30.4.375.
引用本文的文献
1
Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms.用于多重耐药革兰氏阳性微生物的新型抗生素
Microorganisms. 2019 Aug 18;7(8):270. doi: 10.3390/microorganisms7080270.
2
A Multicenter Study To Evaluate Ceftaroline Breakpoints: Performance in an Area with High Prevalence of Methicillin-Resistant Staphylococcus aureus Sequence Type 5 Lineage.一项评估头孢洛林折点的多中心研究：在高流行耐甲氧西林金黄色葡萄球菌 5 型序列型地区的表现。
J Clin Microbiol. 2019 Aug 26;57(9). doi: 10.1128/JCM.00798-19. Print 2019 Sep.
3
Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.头孢洛林酯：在治疗复杂性皮肤和软组织感染及社区获得性肺炎中的应用评价。
Drugs. 2013 Jul;73(10):1067-94. doi: 10.1007/s40265-013-0075-6.
4
Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model.头孢洛林酯在葡萄球菌性小鼠肺炎模型中的疗效。
Antimicrob Agents Chemother. 2012 Dec;56(12):6160-5. doi: 10.1128/AAC.01078-12. Epub 2012 Sep 17.
本文引用的文献
1
Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States.美国耐万古霉素异质性中间水平金黄色葡萄球菌分离株的检测。
J Clin Microbiol. 2011 Dec;49(12):4203-7. doi: 10.1128/JCM.01152-11. Epub 2011 Oct 5.
2
Predictors of clinical virulence in community-onset methicillin-resistant Staphylococcus aureus infections: the importance of USA300 and pneumonia.社区获得性耐甲氧西林金黄色葡萄球菌感染临床毒力的预测因素：USA300 和肺炎的重要性。
Clin Infect Dis. 2011 Oct;53(8):757-65. doi: 10.1093/cid/cir472. Epub 2011 Aug 31.
3
The impact of guidelines on the outcomes of community-acquired and ventilator-associated pneumonia.指南对社区获得性肺炎和呼吸机相关性肺炎结局的影响。
Clin Chest Med. 2011 Sep;32(3):491-505. doi: 10.1016/j.ccm.2011.06.002.
4
Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.评估头孢洛林对体外药代动力学/药效学模型中达托霉素（DAP）不敏感的耐甲氧西林金黄色葡萄球菌（MRSA）菌株的活性。
Antimicrob Agents Chemother. 2011 Jul;55(7):3522-6. doi: 10.1128/AAC.00347-11. Epub 2011 May 16.
5
Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing.以模拟人体给药的方式，在高度耐青霉素肺炎链球菌肺炎兔模型中比较头孢曲松和头孢噻肟的疗效。
Antimicrob Agents Chemother. 2011 Jul;55(7):3557-63. doi: 10.1128/AAC.01773-09. Epub 2011 May 16.
6
In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.人模拟头孢洛林联合 NXL104 方案治疗产超广谱β-内酰胺酶（ESBL）和非产 ESBL 肠杆菌科细菌的体内疗效。
Antimicrob Agents Chemother. 2011 Jul;55(7):3220-5. doi: 10.1128/AAC.00024-11. Epub 2011 Apr 25.
7
Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study.比较头孢洛林对与社区获得性肺炎相关病原体的活性：一项国际监测研究的结果。
J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii69-80. doi: 10.1093/jac/dkr101.
8
Review of ceftaroline fosamil microbiology: integrated FOCUS studies.头孢洛林酯磷酸钠微生物学评价：整合 FOCUS 研究。
J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii45-51. doi: 10.1093/jac/dkr098.
9
Ceftaroline fosamil: a new broad-spectrum cephalosporin.头孢呋辛酯：一种新型的广谱头孢菌素。
J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii11-8. doi: 10.1093/jac/dkr095.
10
Ceftaroline: a comprehensive update.头孢洛林：全面更新。
Int J Antimicrob Agents. 2011 May;37(5):389-95. doi: 10.1016/j.ijantimicag.2011.01.017. Epub 2011 Mar 21.
Zotero 插件